IGF2 signaling and regulation in cancer

被引：123

作者：

Brouwer-Visser, Jurriaan ^{[1
,2
]}

Huang, Gloria S. ^{[1
,2
,3
]}

机构：

[1] Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Div Gynecol Oncol, Bronx, NY 10467 USA

[2] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA

[3] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10467 USA

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2015年 / 26卷 / 03期

关键词：

IGF2; Cancer; Chemoresistance; GROWTH-FACTOR-II; MESSENGER-RNA; BINDING PROTEIN-3; OVARIAN-CANCER; IMPRINTING STATUS; CELL-SURVIVAL; UP-REGULATION; INSULIN; RECEPTOR; EXPRESSION;

D O I：

10.1016/j.cytogfr.2015.01.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Upregulation of IGF2 occurs in both childhood and adult malignancies. Its overexpresssion is associated with resistance to chemotherapy and worse prognosis. IGF2 promoter usage is developmentally regulated; however, malignant tissues are characterized by re-activation of the fetal IGF2 promoters, especially P3. In this review, we describe the mechanisms of IGF2 signaling and regulation in normal and malignant tissues and their clinical implications. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：371 / 377

页数：7

共 79 条

[1]

Amit D, 2013, INT J CLIN EXP MED, V6, P110

[2]

[Anonymous], CLIN CANC RES

[3]

[Anonymous], CLIN CANC RES

[4]

BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O

[5]

Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance [J].

Balch, Curt ;

Nephew, Kenneth P. .

EPIGENETIC ALTERATIONS IN ONCOGENESIS, 2013, 754 :285-311

[6]

Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease [J].

Belfiore, Antonino ;

Frasca, Francesco ;

Pandini, Giusepe ;

Sciacca, Laura ;

Vigneri, Riccardo .

ENDOCRINE REVIEWS, 2009, 30 (06) :586-623

[7]

Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[8]

Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy [J].

Beltran, Pedro J. ;

Calzone, Frank J. ;

Mitchell, Petia ;

Chung, Young-Ah ;

Cajulis, Elaina ;

Moody, Gordon ;

Belmontes, Brian ;

Li, Chi-Ming ;

Vonderfecht, Steven ;

Velculescu, Victor E. ;

Yang, Guorong ;

Qi, Jingwei ;

Slamon, Dennis J. ;

Konecny, Gottfried E. .

CLINICAL CANCER RESEARCH, 2014, 20 (11) :2947-2958

[9]

Brana I, 2014, BR J CANC

[10]

Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer [J].

Brouwer-Visser, Jurriaan ;

Lee, Jiyeon ;

McCullagh, KellyAnne ;

Cossio, Maria J. ;

Wang, Yanhua ;

Huang, Gloria S. .

PLOS ONE, 2014, 9 (06)

← 1 2 3 4 5 6 7 8 →